
NTHI Stock Forecast & Price Target
NTHI Analyst Ratings
Bulls say
NeOnc Technologies Hldgs is well-positioned for growth with strong product candidates, a focus on improving drug delivery to the central nervous system, and a strong financial foundation. The company's promising clinical trials and status as an FDA designated company bode well for their success. With a strong intellectual property portfolio and expected entry into the market in 2030, NeOnc has the potential to make a significant impact in the biopharmaceutical industry.
Bears say
NeOnc Technologies Hldgs is a clinical-stage biopharmaceutical company that has promising drug candidates for brain cancer treatment, but faces significant risks and challenges in its development process. While their lead drug NEO100 has shown an exceptional safety profile and promising efficacy data in a Phase 1 trial, its mechanism of action and potential for combination therapies still need to be fully understood and optimized. Additionally, NeOnc has a complex dosing process for its drugs and may face difficulties in clinical trials and commercial markets. The company is young and has relatively limited financial resources, which may hinder its ability to bring its drugs to market quickly.
This aggregate rating is based on analysts' research of Neonc Technologies Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
NTHI Analyst Forecast & Price Prediction
Start investing in NTHI
Order type
Buy in
Order amount
Est. shares
0 shares